1 / 19

BIOSIGNAL Pty Ltd

Business Plan Evaluation. BIOSIGNAL Pty Ltd. Tove Ringbom Lotta Ekman. Biofilms are colonies of living micro-organisms (e.g., bacteria, fungi, algae, and/or protozoa) growing on any surface (e.g. metals, plastics, tissue, soil particles, teeth, and so forth). What is a biofilm?.

carson
Download Presentation

BIOSIGNAL Pty Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Business Plan Evaluation BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman

  2. Biofilms are colonies of living micro-organisms (e.g., bacteria, fungi, algae, and/or protozoa) growing on any surface (e.g. metals, plastics, tissue, soil particles, teeth, and so forth) What is a biofilm?

  3. Biofilms

  4. How are biofilms formed? http://www.crca.asn.au/activities/2002/conference/Plenary2/Jasjit/Biofilm_Jasjit.swf

  5. cause dental cavities, gum disease, as well as ear-, heart- and lung infections Biofilms also form on contact lenses and on intrauterine birth control devises Biofilms on the inner surfaces of medical equipment (catheters)  hospital infections Biofilm infections

  6. The seaweed (Delisea pulchra) remains slime-free due to the production of furanones Biosignal has patented synthetic analogs of these furanones Furanones prevent bacteria from attaching to surfaces  no biofilm formation The Innovation

  7. http://www.crca.asn.au/activities/2002/conference/Plenary2/Jasjit/PreventionJasjit.swfhttp://www.crca.asn.au/activities/2002/conference/Plenary2/Jasjit/PreventionJasjit.swf

  8. Business Opportunity • By attaching furanones to polymers, biofilm formation could be prevented in • 1) marine and agriculture usages • 2) bound to polymer coatings • 3) in implantable medical devices such as catheters

  9. Evaluating the Business Plan • Plan dated December 6th 2000 • Clear purpose stated • $5.3 million to expand R&D • to hire an experienced chief executive officer • raise money in order to register its patented compounds with the EPA and FDA

  10. Management • Biosignal lacks a CEO at the moment •  Demanding requirements • An experienced polymer chemist must be hired • Professors Kjellberg & Steinberg possess scientific experience in the field of marine biology and microbiology • GM Rohan McDougall

  11. Market Assessment • Biosignal found six different areas of interest:- Household cleaners - Oral care - Contact lens solutions - Anti-foulant in marine paint - Commercial farming applications - Biomaterials

  12. Risks • Biosignals technology may fail to deliver on its early promises • The safety risks to patients and to the environment are not known at this point

  13. Segment for first market entry • Catheter market • The medical grade polymers demonstrate the greatest revenue opportunity of the six different options • The catheter market is growing rapidly, as is the total biomaterials market • Reason for choosing the segment: the disposable catheter is a relatively simple device •  ambition is to move to more technologically advanced medical devices at a later stage

  14. Competitor Information • 156 companies operate on the global catheter market today • Several multinational polymer giants operate in this field • PROBLEM: big organizations such as hospitals generally make group purchases and catheters are often priced as a part of a bundle of products

  15. Collaborations • Biosignal gets office space and lab space support from UNSW and the two Research Directors are employed part time by UNSW • A cooperation project to manufacture Biosignal’s product with an “American specialty chemical manufacturer” • Multinational partners are key success factors for this venture

  16. Financials • Biosignal has established connections to a few companies • Estimated personnel expenses may not be big enough • R&D expenses ought to rise as time goes by - Biosignal is aware

  17. Our conclusion • Start with any of the applications that are outside the human body to get cash flow • The biomaterials market is very tricky • Get experience in manufacturing, sales and running a business before entering the markets that require FDA approval

  18. THANKYOU!

More Related